Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
QuintilesIMS
Cerilliant
Baxter
Accenture
Harvard Business School
Johnson and Johnson
Merck
Daiichi Sankyo

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,318,800

« Back to Dashboard

Which drugs does patent 8,318,800 protect, and when does it expire?

Patent 8,318,800 protects MULTAQ and is included in one NDA.

This patent has fifty patent family members in forty countries.
Summary for Patent: 8,318,800
Title:Solid pharmaceutical compositions containing benzofuran derivatives
Abstract: The present invention relates to a solid pharmaceutical composition for oral administration characterized in that it comprises a benzofuran derivative with antiarrhythmic activity, or one of the pharmaceutically acceptable salts thereof, as an active principle, and a pharmaceutically acceptable nonionic hydrophilic surfactant optionally in combination with one or more pharmaceutical excipients.
Inventor(s): Abramovici; Bernard (Juvignac, FR), Gautier; Jean-Claude (Clapiers, FR), Gromenil; Jean-Claude (Montbazin, FR), Marrier; Jean-Marie (Lattes, FR)
Assignee: Sanofi (Paris, FR)
Application Number:11/955,565
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,318,800
Patent Claim Types:
see list of patent claims
Composition; Dosage form;

Drugs Protected by US Patent 8,318,800

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Sanofi Aventis Us MULTAQ dronedarone hydrochloride TABLET;ORAL 022425-001 Jul 1, 2009 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,318,800

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France97 07795Jun 23, 1997

Non-Orange Book US Patents Family Members for Patent 8,318,800

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,323,493 Solid pharmaceutical composition containing benzofuran derivatives ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Baxter
Johnson and Johnson
Fuji
Chinese Patent Office
UBS
Federal Trade Commission
US Army
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.